Product Pipeline Compound Platform Indication Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA Partner Pidnarulex CX-5461 G-quadruplex (stabilizer) Ovarian Cancer/Breast/Other Cancer Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA/CA Pidnarulex CX-5461 G-quadruplex (stabilizer) Solid Tumors Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA NCI-NExT Pidnarulex CX-5461 G-quadruplex (stabilizer) MYC aberrant B-cell lymphoma Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA NCI-NExT Pidnarulex CX-5461 G-quadruplex (stabilizer) Refractory Microsatellite Stable Colorectal Cancer Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA NCI-NExT Pidnarulex CX-5461 G-quadruplex (stabilizer) Breast Cancer (Completed) Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA CA Dream team/CCTG Pidnarulex CX-5461 G-quadruplex (stabilizer) Haematologic Malignancies (Completed) Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA AU PMCC Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) Cholangiocarcinoma (Completed) Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA/KR/TW Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) Basal cell carcinoma Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) Medulloblastoma Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA PBTC/Stanford Univ. Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) Neuroblastoma Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA USA PSU/BCC/Four Diamonds Foundation